Table 4.

Association between BMI and hormones stratified by menopausal status (mean ±SE) among a sample of 667 women with breast cancer

BMI < 25 (n = 284)BMI = 25-30 (n = 216)BMI > 30 (n = 210)P for trend
C-peptide (ng/mL)
    Premenopausal1.54 ± 0.091.92 ± 0.11*2.69 ± 0.13,0.0001
    Postmenopausal1.89 ± 0.072.45 ± 0.08*2.95 ± 0.08,0.0001
Leptin (ng/mL)
    Premenopausal10.8 ± 1.418.7 ± 1.7*36.9 ± 2.0,0.0001
    Postmenopausal13.4 ± 0.924.8 ± 1.0*43.0 ± 1.1,0.0001
IGF-I (ng/mL)
    Premenopausal168.7 ± 6.6166.0 ± 8.1149.4 ± 9.70.11
    Postmenopausal134.9 ± 3.6128.9 ± 4.0110.1 ± 4.2,0.0001
IGFBP-3 (μg/mL)
    Premenopausal4.09 ± 0.104.10 ± 0.164.31 ± 0.150.24
    Postmenopausal4.10 ± 0.074.07 ± 0.074.00 ± 0.080.33
IGF-I:IGFBP-3
    Premenopausal41.5 ± 1.440.3 ± 1.735.1 ± 2.0,0.013
    Postmenopausal32.8 ± 0.731.7 ± 0.827.7 ± 0.8,0.0001
  • NOTE: Sample sizes for premenopausal women: BMI < 25 (n = 63), BMI = 25-30 (n = 41), and BMI > 30 (n = 30). Sample sizes for postmenopausal women: BMI < 25 (n = 210), BMI = 25-30 (n = 165), and BMI > 30 (n = 158). Adjusted for study site, age, ethnicity, education, disease stage, adjuvant treatment, tamoxifen use, type 2 diabetes, smoking status, and sports/recreational MET-hours per week.

  • * P < 0.05, BMI = 25-29.9 significantly different from BMI < 25.

  • P < 0.05, BMI > 30 significantly different from BMI < 25.

  • P < 0.05, BMI > 30 significantly different from BMI = 25.0-29.9.